| Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ... New England Journal of Medicine 363 (18), 1693-1703, 2010 | 5558 | 2010 |
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors LV Sequist, BA Waltman, D Dias-Santagata, S Digumarthy, AB Turke, ... Science translational medicine 3 (75), 75ra26-75ra26, 2011 | 3821 | 2011 |
| Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ... Journal of clinical oncology 27 (26), 4247-4253, 2009 | 2515 | 2009 |
| ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers K Bergethon, AT Shaw, SH Ignatius Ou, R Katayama, CM Lovly, ... Journal of clinical oncology 30 (8), 863-870, 2012 | 2034 | 2012 |
| International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology T Shimosegawa, ST Chari, L Frulloni, T Kamisawa, S Kawa, ... Pancreas 40 (3), 352-358, 2011 | 1780 | 2011 |
| Functional genomics reveal that the serine synthesis pathway is essential in breast cancer R Possemato, KM Marks, YD Shaul, ME Pacold, D Kim, K Birsoy, ... Nature 476 (7360), 346-350, 2011 | 1753 | 2011 |
| Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases JN Vauthey, TM Pawlik, D Ribero, TT Wu, D Zorzi, PM Hoff, HQ Xiong, ... Journal of clinical oncology 24 (13), 2065-2072, 2006 | 1597 | 2006 |
| Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers R Katayama, AT Shaw, TM Khan, M Mino-Kenudson, BJ Solomon, ... Science translational medicine 4 (120), 120ra17-120ra17, 2012 | 1519 | 2012 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1427 | 2018 |
| EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non–small cell lung cancer: a retrospective analysis JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli, Z Piotrowska, ... Clinical cancer research 22 (18), 4585-4593, 2016 | 1236 | 2016 |
| Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ... Cancer discovery 6 (10), 1118-1133, 2016 | 1207 | 2016 |
| EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib RB Corcoran, H Ebi, AB Turke, EM Coffee, M Nishino, AP Cogdill, ... Cancer discovery 2 (3), 227-235, 2012 | 1161 | 2012 |
| Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy C Pfirschke, C Engblom, S Rickelt, V Cortez-Retamozo, C Garris, F Pucci, ... Immunity 44 (2), 343-354, 2016 | 977 | 2016 |
| Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population SJ Rodig, M Mino-Kenudson, S Dacic, BY Yeap, A Shaw, JA Barletta, ... Clinical cancer research 15 (16), 5216-5223, 2009 | 874 | 2009 |
| Patient-derived models of acquired resistance can identify effective drug combinations for cancer AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ... Science 346 (6216), 1480-1486, 2014 | 822 | 2014 |
| mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake ÖH Yilmaz, P Katajisto, DW Lamming, Y Gültekin, KE Bauer-Rowe, ... Nature 486 (7404), 490-495, 2012 | 822 | 2012 |
| PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project MS Tsao, KM Kerr, M Kockx, MB Beasley, AC Borczuk, J Botling, ... Journal of Thoracic Oncology 13 (9), 1302-1311, 2018 | 772 | 2018 |
| ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer JF Gainor, AM Varghese, SHI Ou, S Kabraji, MM Awad, R Katayama, ... Clinical cancer research 19 (15), 4273-4281, 2013 | 683 | 2013 |
| RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ... Nature communications 6 (1), 6377, 2015 | 629 | 2015 |
| Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor D Juric, P Castel, M Griffith, OL Griffith, HH Won, H Ellis, SH Ebbesen, ... Nature 518 (7538), 240-244, 2015 | 614 | 2015 |
